Trial Profile
An open-label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study comparing pharmacokinetic and pharmacodynamic effects of PEG Neutrogen (pegfilgrastim) of Virchow Biotech, India with that of Neulastim (pegfilgrastim) of Roche following 6 mg subcutaneous injection in healthy, adult human subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Virchow Group
- 26 Aug 2016 New trial record